- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04263116
Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae
Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae; Clinical Efficacy and Complications: Randomized Prospective Study
Background: There are several studies that document the safety and efficacy of the balloon-assisted maturation (BAM) technique. Ultimately, there are also studies that report its possible negative consequences such as fibrosis and restenosis of venous outflow, leading to malfunctioning arteriovenous fistula (AVF). Thus, in an effort to increase the number of primary AVFs, shorten maturation times, and reduce the number of indwelling catheters, we ascertain the BAM technique within this study to optimize access care and maximize use of AVFs. The balloon assisted maturation approach specifically and aggressively dilates the entire usable segment of the AVF.
Methods: This is a randomized prospective study conducted in the department of vascular surgery, Mansoura University Hospitals, including patients with hemodialysis access creation between June 2017 and May 2019. Three hundred patients were recruited from a total of 648 primary AVF creation cases. Patients were divided into two groups; Group (A) Balloon assisted maturation (BAM) (n=157) 52.3 % technique had been done while in the other Group (B) the usual maneuver was used (NO BAM) (n=143) 47.7%. Preoperative duplex was done for all cases to assess suitability. Intraoperative venography was the initial step following surgical exposure of the assigned veins to ascertain continuity and unlimited flow of the superficial vein. Balloon dilatation by 1 mm larger than the size of the vein, sparing the spatulated end of the vein followed by post-dilatation venography to reveal any injury and assess the success of dilatation process. All cases were completed as an end to side anastomosis. Patients were followed clinically and radiologically at regular visits in the 2nd, 4th and 6th week post-procedure, assessing the flow rate, vein depth and diameter via duplex US examination.
Results: Patients age ranged from 19 to 89 (mean 51.17 ±15.5) years. The average maturation time was 3.7 weeks (SD ± 1.3 w) and 5.91 weeks (SD ± 2.2 w) for the BAM and non-BAM groups, respectively. Eighty-seven cases (88.7 %) with a pre-operative vein diameter of 3 mm or less, that underwent BAM showed early maturation and started dialysis within 2-4 weeks (68 cases 70%). On the other hand, 28 cases (45.2%) with a vein diameter equal or less than 3 mm in the NO BAM group failed to get mature. Both successful functional maturation (95%) and complication rates (9.6 %) were higher among cases of the BAM group compared to 80.4% maturation rate and 5 % complication in the NO BAM group. The higher complication rate may be attributed to the large number of cases.
Conclusion: Balloon-assisted maturation has a pivotal role to help the dialysis society meet the goals of the Fistula First Initiative; It can achieve an accelerated functional maturation of AVF in cases of small caliber veins, with access to early dialysis, thus decreasing the indwelling catheter-related complications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
INTRODUCTION:
End-stage renal disease (ESRD) is the crossing point of multiple heterogeneous disease pathways that can alter the structure and function of the kidneys irreversibly. Both definition and classification of ESRD have been developing over time. However, current international guidelines define ESRD as declined kidney function shown by GFR of less than 60 mL/min per 1•73 m², kidney damage markers or both, for at least 3 months duration, regardless of underlying cause.1 Haemodialysis (HD) is a lifeline management for patients with ESRD. A critical factor in the survival of renal dialysis patients is the surgical creation of vascular access, and international guidelines recommend arteriovenous fistulas (AVF) as the gold standard vascular access for haemodialysis. Arteriovenous graft and central vein catheters have higher primary patency rates compared to AVF, however native AVFs last longer. 3 There is conflicting evidence about the impact of various demographic characteristics of the patients on the functional maturation of the native AVFs. Certain characteristics such as diabetes mellitus, female gender, thrombophilia and various hematological factors, such as platelet count and hemoglobin levels, can affect fistula maturation. Also the impact of certain operative and anatomical factors, including but not limited to diameter of artery and venous limb of the AVF, presence of palpable thrill, audible bruit, and anatomical site of fistula may affect outcome.4 Functional fistula maturation is defined as patent fistula, ready for cannulation with vein length of at least 10 cm long segment, diameter more than 6 mm, depth not more than 6 mm and ability of the access to deliver a flow rate of 350 to 400 ml/min and maintain dialysis for 3.5 to 4 hours.5 Delayed maturation of AVF among patients who require hemodialysis can lead to catheter sepsis with its resultant morbidity and mortality. Some authors have proposed that sequential BAM may accelerate maturation process and shorten the maturation times of these accesses.6 Balloon angioplasty maturation is emerging as a surgical technique that could increase utilization and improve function of autogenous arteriovenous hemodialysis accesses. This approach includes primary balloon angioplasty (PBA) of small veins during AVF creation.9-10 However there are no studies that directly compare maturation times for AVF with and without using BAM. There are several studies that document the safety and efficacy of the BAM technique. 7 Ultimately, there are also studies that report its possible negative consequences such as fibrosis and restenosis of venous outflow, leading to malfunctioning AVF. 8 Thus, in an effort to increase the number of primary AVFs, shorten maturation times, and reduce the number of indwelling catheters, we ascertain the BAM technique within this study to optimize access care and maximize use of AVFs.
Patients and Methods:
This is a randomized prospective study conducted in the department of vascular surgery, Mansoura university hospitals. Between July 2017 and May 2019 Three hundred patients were recruited from a total of 648 primary AVF creation cases. Patients had been advised to undergo elective surgery for AVF once their renal glomerular filtration rate estimated (eGFR) is less than 15 ml/min. Block randomization was the method used for stratification of patients' groups.
Inclusion and exclusion criteria: All patients aged 18 years or older who need AVF formation in the upper limb were included as a recruitment target. In patients with multiple episodes of AVF creation, each episode was considered separately and data from the corresponding episode had been recorded in our data sheet. Patients who underwent salvage procedures to improve maturation, i.e. secondary maturation, or those who could not give informed consent were not included1. A total of 335 patients who needed Autogenous AVF were enrolled in the study during that period.
Patients and methods Table (1) shows the patient's demographics, including underlying medical conditions, previous AVF, transplanted kidney and other associated morbidity. Arterial assessments included pulse examination, segmental blood pressures in both upper extremities, and the modified Allen test for continuity of the palmar arch. Venous assessments include gross evaluation of the veins in the dependent position with tourniquet enhancement in the upper arm. Table (2) shows patients' workup including blood picture, blood sugar level, kidney functions, liver functions and coagulation profile.
Duplex US examination checked the diameter, compressibility, depth, and continuity of the arm veins. Arterial assessment included radial and brachial arterial size, presence or absence of calcification, segmental pressure, and velocity wave forms.
Operative procedure:
The non dominant upper limb was preferred and saved. AVFs were created at wrist, forearm and arm in both male and female patients under local, regional or general anaesthesia. All brachiobasilic fistulas were created in one stage.
Randomization was done through computer generated block serials in sealed envelopes which were opened when the patient was on the operating table. During AVF creation and before anastomosis, the vein was cannulated through the open end of the venotomy. Intraoperative venography was done to assess the vein in the BAM group only. Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein. Post venoplasty venography was done to reveal any injury and assess the dilatation process. All cases were completed as an end to side anastomosis followed by assessment of the dilated segment for any spasm which is treated by mechanical compression of the vein cephalad to the area of concern. Patients were discharged home on the following day with instructions for care of fistula.These instructions included avoidance of any blood sampling, using this arm for blood pressure measurement, clothes with constrictive sleeves, heavy or tight jewellery, circumferential dressings on wound and sleeping on the operated arm. Patients were taught how to feel for the thrill, advised to contact the operating team if they developed any numbness in hand, discoloration of fingertips or coldness. All patients were instructed to commence active hand ball exercises before discharge from hospital. Patients were followed both clinically and radiologically with duplex scan at the 2nd, 4th and 6th weeks post-procedure, checking the flow rate, depth and diameter of the target vein.
Statistical analysis: Data was analysed using Statistical Package for the Social Sciences. The numerical outcomes e.g. age was calculated as mean. Chi Square test was used to assess the association of various parameters. Results were considered statistically significant if the p-value was found to be less than or equal to 0.05. Log rank test (mantel cox) test was used to compare AVF maturation in both groups
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mansoura, Egypt, 35511
- Mansoura University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Any patient who need arterio-venous fistula formation in the upper limb
Exclusion Criteria:
- Patients who underwent salvage procedures to improve maturation, i.e. secondary maturation
- Those who could not give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAM group
Balloon assisted maturation
|
Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein.
BAM is performed over the whole length of the vein sparing the spatulated end of the vein
|
Experimental: NO BAM
NO Balloon assisted maturation
|
Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein.
BAM is performed over the whole length of the vein sparing the spatulated end of the vein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flow rate of the target vein
Time Frame: 6 weeks
|
Radio-logically measure the flow rate in the vein
|
6 weeks
|
Diameter of the target vein
Time Frame: 6 weeks
|
Radio-logically measure the vein diameter
|
6 weeks
|
Depth of the target vein
Time Frame: 6 weeks
|
Radio-logically measure the vein depth from the skin
|
6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R. 17.12.44
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis Access Failure
-
National Taiwan University Hospital Hsin-Chu BranchCompletedHemodialysis Access Failure
-
Brigham and Women's HospitalNot yet recruitingHemodialysis Access FailureUnited States
-
Egyptian Biomedical Research NetworkCompletedHemodialysis Access FailureEgypt
-
Assiut UniversityUnknownHemodialysis Access Failure
-
The University of QueenslandAustralasian Kidney Trials NetworkActive, not recruitingVascular Access Complication | Hemodialysis Access Failure (Disorder)Netherlands, Switzerland, Canada, France, United Kingdom, Australia, Malaysia
-
National Taiwan University Hospital Hsin-Chu BranchUnknownHemodialysis Access Failure | Blood Pressure | Dialysis Access MalfunctionTaiwan
-
National Taipei University of Nursing and Health...UnknownHemodialysis Access Failure | Renal Dialysis | Integrative MedicineTaiwan
-
Shanghai Zhongshan HospitalUnknownHemodialysis Access Failure | Hemodialysis ComplicationChina
-
National Taiwan University Hospital Hsin-Chu BranchUnknownHemodialysis Access Failure (Disorder) | Stent-Graft Restenosis | Arteriovenous Graft | Drug-coated BalloonTaiwan
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingHemodialysis Access Failure | Dialysis Access Malfunction | Vascular Access Malfunction | Hemodialysis Fistula ThrombosisNetherlands
Clinical Trials on Balloon Assisted Maturation
-
Shanghai Jiao Tong University School of MedicineUnknownGastrointestinal Vascular MalformationChina
-
Batzofin Fertility ServicesSuspended
-
Second Affiliated Hospital of Wenzhou Medical UniversityUnknownTibial Fractures | Arthroscopy | Orthopedic | Fracture Fixation
-
Radboud University Medical CenterPENTAX Europe GmbHRecruitingAdenoma | Artificial Intelligence | Colonoscopy | Colorectal PolypNetherlands
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruiting
-
Northwell HealthWithdrawnPolycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)United States
-
Ajou University School of MedicineCompletedBiliary Tract Diseases | Bile Duct Neoplasms | Choledocholithiasis | Roux-en-Y AnastomosisKorea, Republic of
-
Bruce Rose, MDRecruitingPolycystic Ovary SyndromeUnited States
-
Hillel Yaffe Medical CenterCompletedPolycystic Ovarian SyndromeIsrael
-
Medical College of WisconsinMicrovention-Terumo, Inc.WithdrawnAneurysm | Intracranial Aneurysms | Brain AneurysmUnited States